BREATHE-PH study aims to unlock secrets of lung blood pressure in heart failure

NCT ID NCT07537517

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a specific biological pathway (BMPR2-activin) affects pulmonary hypertension in people with left heart disease. Researchers will follow 150 heart failure patients for one year, using blood tests, imaging, and heart tissue analysis. The goal is to better understand the disease and find new ways to treat it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could redefine how pulmonary hypertension is classified and point toward new targeted therapies like activin inhibitors.

What could go wrong

This is an observational study, not a treatment trial. It will not directly test any therapy, and results may not lead to immediate clinical changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Hospital GU Gregorio Marañón

    RECRUITING

    Madrid, Madrid, 28007, Spain

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••